Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04852822 · ClinicalTrials.gov registry record
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A clinical trial, sponsored by University of Washington.
- Terminated
- Registry status
- 350
- Enrollment target
NCT04852822 is a clinical trial that was terminated before completion, run by University of Washington. The registered enrollment target is 350 participants.
The verdict
NCT04852822 was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- 350 participants
- Enrollment target
Study Summary
This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the medications used to treat these conditions may change the way vaccines work in a patient's body. The purpose of this study is to find out if patients with CLL/SLL make antibodies, or have an immune response, to the SARS-CoV-2 vaccines. Information gained from this study may help researchers better understand how effective the vaccines work in preventing COVID-19 (coronavirus disease 2019) in patients with CLL and SLL.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2024-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04852822
The ClinicalTrials.gov registry entry for NCT04852822 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04852822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04852822 about?
NCT04852822 is a clinical study titled "Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the m...
What is the current status of trial NCT04852822?
This trial is currently terminated. The enrollment target is 350 participants. The study started on 2021-03-18. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT04852822?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT04852822?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.